Trevena (NASDAQ:TRVN) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Thursday. The firm currently has a $1.50 price objective on the biopharmaceutical company’s stock. Zacks Investment Research‘s price target would indicate a potential upside of 6.38% from the stock’s previous close.

According to Zacks, “Trevena, Inc. is a biopharmaceutical company. It focuses on discovering and developing therapeutics for G protein coupled receptors. The Company’s product pipeline includes TRV027, TRV130, TRV734 and Delta opioid biased ligand which are in different clinical phases. Trevena, Inc. is based in King of Prussia, Pennsylvania. “

Several other research firms have also recently commented on TRVN. Jefferies Financial Group cut Trevena from a “buy” rating to a “hold” rating and reduced their price target for the company from $10.00 to $1.00 in a report on Wednesday, October 10th. JMP Securities raised their price target on Trevena from $4.00 to $15.00 and gave the company an “outperform” rating in a report on Friday, October 12th. Needham & Company LLC cut Trevena from a “buy” rating to a “hold” rating in a report on Friday, October 12th. Finally, HC Wainwright reduced their price target on Trevena from $7.00 to $3.00 and set a “buy” rating for the company in a report on Friday, October 12th. Four equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Trevena currently has an average rating of “Buy” and a consensus target price of $5.54.

TRVN opened at $1.41 on Thursday. The company has a quick ratio of 4.30, a current ratio of 4.30 and a debt-to-equity ratio of 0.16. The company has a market capitalization of $116.07 million, a PE ratio of -1.17 and a beta of 2.62. Trevena has a 12 month low of $0.38 and a 12 month high of $3.58.

Trevena (NASDAQ:TRVN) last posted its quarterly earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.07. The business had revenue of $3.00 million during the quarter, compared to analyst estimates of $3.00 million. As a group, research analysts forecast that Trevena will post -0.37 EPS for the current fiscal year.

In other news, Director Leon O. Moulder, Jr. acquired 100,000 shares of Trevena stock in a transaction that occurred on Friday, February 1st. The stock was purchased at an average cost of $1.02 per share, with a total value of $102,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Maxine Gowen acquired 50,000 shares of Trevena stock in a transaction that occurred on Friday, February 1st. The shares were purchased at an average cost of $1.02 per share, with a total value of $51,000.00. The disclosure for this purchase can be found here. 4.60% of the stock is owned by company insiders.

A number of hedge funds have recently modified their holdings of TRVN. Virtu Financial LLC acquired a new position in Trevena during the fourth quarter worth $82,000. Renaissance Technologies LLC raised its holdings in Trevena by 264.1% during the second quarter. Renaissance Technologies LLC now owns 521,700 shares of the biopharmaceutical company’s stock worth $751,000 after purchasing an additional 378,400 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in Trevena by 17.5% during the third quarter. JPMorgan Chase & Co. now owns 541,099 shares of the biopharmaceutical company’s stock worth $1,147,000 after purchasing an additional 80,437 shares during the last quarter. Millennium Management LLC raised its holdings in Trevena by 112.3% during the second quarter. Millennium Management LLC now owns 1,005,820 shares of the biopharmaceutical company’s stock worth $1,448,000 after purchasing an additional 532,129 shares during the last quarter. Finally, BlackRock Inc. raised its holdings in Trevena by 151.4% during the third quarter. BlackRock Inc. now owns 1,873,311 shares of the biopharmaceutical company’s stock worth $3,971,000 after purchasing an additional 1,128,041 shares during the last quarter. 37.96% of the stock is owned by hedge funds and other institutional investors.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, develops therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. Its product candidates include OLINVO injection, a G protein biased ligand of the µ opioid receptor that has completed Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is preferred; TRV250, a G protein biased ligand targeting the d-receptor, which is in Phase I clinical study for the treatment of migraine; and TRV734, a small molecule G protein biased ligand of the µ opioid receptor that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain, as well as TRV027 for the treatment of acute heart failure.

Read More: Does the Step Transaction Doctrine Affect a Backdoor Roth IRA?

Get a free copy of the Zacks research report on Trevena (TRVN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Trevena (NASDAQ:TRVN)

Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.